Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Short term Debt (2019 - 2022)

Theravance Biopharma (TBPH) has disclosed Short term Debt for 4 consecutive years, with $9.0 million as the latest value for Q1 2022.

  • On a quarterly basis, Short term Debt fell 22.7% to $9.0 million in Q1 2022 year-over-year; TTM through Mar 2022 was $9.0 million, a 22.7% decrease, with the full-year FY2020 number at $19.3 million, up 96.26% from a year prior.
  • Short term Debt was $9.0 million for Q1 2022 at Theravance Biopharma, down from $12.5 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $19.3 million in Q4 2020 to a low of $6.9 million in Q2 2021.
  • A 4-year average of $11.0 million and a median of $9.9 million in 2019 define the central range for Short term Debt.
  • Peak YoY movement for Short term Debt: surged 96.26% in 2020, then decreased 22.7% in 2022.
  • Theravance Biopharma's Short term Debt stood at $9.9 million in 2019, then soared by 96.26% to $19.3 million in 2020, then plummeted by 35.19% to $12.5 million in 2021, then decreased by 28.08% to $9.0 million in 2022.
  • Per Business Quant, the three most recent readings for TBPH's Short term Debt are $9.0 million (Q1 2022), $12.5 million (Q3 2021), and $6.9 million (Q2 2021).